Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
Lin H Soe, Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, University of California, Davis, Sacramento, CA, USA Abstract: Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor...
Saved in:
Main Authors: | Soe LH (Author), Wurz GT (Author), Kao CJ (Author), DeGregorio MW (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ospemifene for vulvar and vaginal atrophy: an overview
by: Santiago Palacios
Published: (2020) -
Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles
by: María del Carmen Pingarrón Santofimia, et al.
Published: (2020) -
Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
by: Mariella Lilue, et al.
Published: (2020) -
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
by: Palacios S, et al.
Published: (2016) -
Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
by: Zuramis Estrada Blanco, et al.
Published: (2020)